{
    "ticker": "TVTX",
    "name": "Travere Therapeutics, Inc.",
    "description": "Travere Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases. Founded in 2019 and headquartered in San Diego, California, Travere aims to address unmet medical needs in conditions such as kidney diseases, metabolic disorders, and other serious health challenges. The company\u2019s lead product, Sparsentan, is a dual acting therapy that targets both the angiotensin II receptor and endothelin receptor, designed to treat focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease. Travere\u2019s commitment to patient-centric solutions drives its research pipeline, which includes several candidates in various stages of clinical development targeting rare and serious diseases. The company actively collaborates with patient advocacy groups and healthcare professionals to ensure that the voices of patients are heard and their needs are prioritized in drug development. Travere's mission is to transform the lives of patients with rare diseases through the discovery and development of innovative therapies that improve health outcomes and quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2019",
    "website": "https://www.traversetherapeutics.com",
    "ceo": "Eric Dube",
    "social_media": {
        "twitter": "https://twitter.com/TravereTx",
        "linkedin": "https://www.linkedin.com/company/travere-therapeutics/"
    },
    "investor_relations": "https://investors.traversetherapeutics.com",
    "key_executives": [
        {
            "name": "Eric Dube",
            "position": "CEO"
        },
        {
            "name": "Jules A. E. D. S. V. De Jongh",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Sparsentan"
            ]
        }
    ],
    "seo": {
        "meta_title": "Travere Therapeutics, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Travere Therapeutics, Inc., focused on developing innovative therapies for rare diseases. Learn about Sparsentan and our commitment to patient needs.",
        "keywords": [
            "Travere Therapeutics",
            "Rare Diseases",
            "Sparsentan",
            "Biotech",
            "Pharmaceuticals",
            "FSGS"
        ]
    },
    "faq": [
        {
            "question": "What is Travere Therapeutics known for?",
            "answer": "Travere Therapeutics is known for developing innovative therapies for rare diseases, particularly its lead product Sparsentan."
        },
        {
            "question": "Who is the CEO of Travere Therapeutics?",
            "answer": "Eric Dube is the CEO of Travere Therapeutics, Inc."
        },
        {
            "question": "Where is Travere Therapeutics headquartered?",
            "answer": "Travere Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Sparsentan used for?",
            "answer": "Sparsentan is a dual acting therapy designed to treat focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease."
        },
        {
            "question": "When was Travere Therapeutics founded?",
            "answer": "Travere Therapeutics was founded in 2019."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "BMRN",
        "VRTX"
    ],
    "related_stocks": [
        "ABBV",
        "REGN",
        "NVS",
        "JAZZ"
    ]
}